Guobang Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 670 million yuan, a year-on-year increase of 15.78%

According to the Zhitong Finance APP, Guobang Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.47 billion yuan, a year-on-year increase of 1.17%. The net profit attributable to shareholders of the listed company was 670 million yuan, a year-on-year increase of 15.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 619 million yuan, a year-on-year increase of 9.59%